Linked Life Data

1611644

Source:http://linkedlifedata.com/resource/pubmed/id/1611644

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1992-7-27
pubmed:abstractText
Recent data suggest that non-insulin-dependent diabetes mellitus (NIDDM) may evolve in genetically predisposed individuals beginning with impaired peripheral glucose metabolism followed by insulin deficiency. Glyburide is an effective, long-acting, second-generation oral sulfonylurea introduced in the United States in 1984. In comparison with the first-generation sulfonylureas, glyburide is at least as effective, has a lower incidence of side effects, and may enhance postreceptor insulin activity to a greater degree. Glyburide can improve glycemic control, as evidenced by reduced fasting blood glucose concentrations and glycohemoglobin levels, without the inconvenience of insulin injections, the higher plasma insulin concentrations, and the additional training required to administer insulin. Because of its ability to enhance target tissue insulin action, glyburide also improves glycemic control in many NIDDM patients who have previously failed therapy with other sulfonylurea agents. Gluburide, as adjunctive therapy, may reduce the daily dosage needed by those who require insulin. Favorable pharmacokinetics and high inherent potency of glyburide often allow effective therapy when the drug is administered once a day.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0149-2918
pubmed:author
pubmed:issnType
Print
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
196-213
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:articleTitle
Glyburide in non-insulin-dependent diabetes: an update.
pubmed:affiliation
Department of Medicine, University of California, San Diego.
pubmed:publicationType
Journal Article, Comparative Study, Review